



High-pressure, non compliant balloon angioplasty for long and calcified infrapopliteal and inframalleolar lesions is feasible

Huizing, Eline; Kum, Steven; Adams, George; Ferraresi, Roberto; de Vries, Jean Paul P.M.; Ünlü, Çağdaş

Published in: International angiology

DOI: 10.23736/S0392-9590.20.04375-8

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version Publisher's PDF, also known as Version of record

Publication date: 2020

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA): Huizing, E., Kum, S., Adams, G., Ferraresi, R., de Vries, J. P. P. M., & Ünlü, Ç. (2020). High-pressure, non compliant balloon angioplasty for long and calcified infrapopliteal and inframalleolar lesions is feasible. *International angiology*, *39*(5), 390-397. https://doi.org/10.23736/S0392-9590.20.04375-8

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverneamendment.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

© 2020 EDIZIONI MINERVA MEDICA Online version at http://www.minervamedica.it International Angiology 2020 October;39(5):390-7 DOI: 10.23736/S0392-9590.20.04375-8

ORIGINAL ARTICLE PERIPHERAL ARTERIAL DISEASE

High-pressure, non compliant balloon angioplasty for long and calcified infrapopliteal and inframalleolar lesions is feasible

Eline HUIZING¹*, Steven KUM², George ADAMS³, Roberto FERRARESI⁴, Jean-Paul P. M. DE VRIES⁵, Çağdaş ÜNLÜ¹

¹Department of Surgery, Northwest Clinics, Alkmaar, the Netherlands; ²Vascular Service, Department of Surgery, Changi General Hospital, Singapore; ³Rex Healthcare, Raleigh, NC, USA; ⁴Peripheral Interventional Unit, Humanitas Gavazzeni, Bergamo, Italy; ⁵Division of Vascular Surgery, Department of Surgery, University Medical Center Groningen, Groningen, the Netherlands

*Corresponding author: Eline Huizing, Northwest Clinics Alkmaar, Department of Surgery, Wilhelminalaan 12, 1815 JD, Alkmaar, the Netherlands. E-mail: e.huizing@nwz.nl

ABSTRACT

Background: To evaluate the safety, feasibility and effectiveness of high-pressure, noncompliant balloon angioplasty in the management of long infrapopliteal calcified lesions.

Methods: Consecutive patients, presenting with chronic limb-threatening ischemia (CLTI) and long (>100 mm) calcified infrapopliteal lesions who were treated with a high pressure, noncompliant balloon (JADE, OrbusNeich, Hong Kong) between January 2016 and July 2016 were retrospectively analyzed. Angioplasty was performed by inflating the balloon to a pressure of 22 to 24 atm for 90 seconds. Primary outcome was technical success. Secondary outcomes were procedure-related complications, limb salvage, amputation-free survival (AFS), wound healing, overall survival, freedom from clinically driven target lesion reintervention (CD-TLR), and resolution of CLTI at 2 and 3 years.

Results: Overall, 23 lesions in 21 limbs of 20 patients were treated. All patients had tissue loss (Rutherford 5 or 6). The mean lesion length was 374.8 mm. Of all lesions, 56.5% were occlusions, 91.3% were classified as TransAtlantic Inter-Society Consensus (TASC) C and D lesions, and 78.3% had severe calcification classification. Of all lesions, 52.2% extended into the below-the-ankle arteries. Technical success was achieved in 22 lesions (95.7%). There were no procedure-related complications. No bailout stenting was required. At 2 and 3 years, limb salvage was 84.7% and 78.7%, AFS was 71.4% and 56.1%, wound healing was 81.0% and 85.7%, overall survival was 75.0% and 64.3% and freedom from CD-TLR was 77.6% and 63.5%, respectively. Resolution of CLTI without TLR was 81.0% at 2 and 3 years.

Conclusions: This study is the first to analyze safety and feasibility of a high-pressure, noncompliant balloon for long, calcified infrapopliteal and inframalleolar lesions.

HIGH-PRESSURE, NON COMPLIANT BALLOON ANGIOPLASTY

(*Cite this article as:* Huizing E, Kum S, Adams G, Ferraresi R, de Vries JPP, Ünlü C. High-pressure, non compliant balloon angioplasty for long and calcified infrapopliteal and inframalleolar lesions is feasible. Int Angiol 2020;39:390-7. DOI: 10.23736/S0392-9590.20.04375-8)

Key words: Critical limb ischemia; Peripheral arterial disease; Vascular calcification; Balloon angioplasty; Endovascular procedures.

Revascularization is essential in treating chronic limbthreatening ischemia (CLTI) patients and can be performed surgically or with an endovascular procedure. In infrapopliteal arteries, endovascular therapy is the initial choice for revascularization with plain old balloon angioplasty (POBA) as the primary choice to perform the procedure with.

However, PTA using POBA is not always successful in treating infrapopliteal lesions in CLTI patients.¹ Technical failure rates of 13.3% are not uncommon and increase when applied for TransAtlantic Inter-Society Consensus (TASC) type D lesions, due to recoil, residual stenosis or failure of balloon expansion.¹⁻⁴

Another limitation of the treatment of POBA in infrapopliteal arteries, is the recurrent need for interventions. A recent meta-analysis found a target lesion reintervention rate of 27.8% at 1 year of follow-up.⁵ The high reintervention rate could possibly be due to clinically relevant restenosis from inadequate balloon expansion or recoil at the time of index procedure which occurs more commonly than expected.⁶

Atherectomy devices and plaque modifying balloons were developed to deal with the atherosclerotic plaque when POBA fails. However, there is no evidence to support the superiority of these devices over POBA.^{7, 8} Other treatment modalities are drug eluting stents (DES) for consideration when POBA fails. A meta-analysis by Varcoe *et al.*⁹ reported improved primary patency and freedom from reintervention rates of DES compared to POBA in infrapopliteal arteries at 1 year. Despite that, long-term studies reported lack these improved rates at 3 years of follow-up,^{10, 11} resulting DES to be left as a bail-out option.

A potential treatment option for long and severely calcified infrapopliteal lesions may be the JADE (OrbusNeich, Hong Kong, China) balloon. This is a non-compliant balloon with a rated burst pressure of 22 atm and designed for controlled opening of resistant lesions in the peripheral arteries. Similar high-pressure balloons have previously been applied in coronary studies, which showed high pressure balloons to be safe with a procedural success percentage of 96.6% in heavily resistant coronary lesions.^{12, 13}

This study evaluated the safety, feasibility and mid-term effectiveness of a high-pressure, noncompliant balloon for the treatment of long, infrapopliteal and inframalleolar lesions in CLTI patients.

Materials and methods

This study was conducted according to the principles of the Declaration of Helsinki and approved by the Institutional Review Board of the Changi General Hospital (IRB number: 2019/2448). The requirement for informed consent was waived by the committee.

Patient selection

All consecutive CLTI patients who were treated with the JADE balloon for long calcified lesions in the Changi General Hospital in Singapore between January 2016 and July 2016 were included in this study. CLTI was defined as the presence of peripheral arterial disease (PAD) in combination with gangrene, a lower limb ulceration >2 weeks duration or rest pain with affirmative hemodynamic studies.⁷ Three dedicated vascular surgeons with broad experience in endovascular techniques performed the procedures. The decision to use the high-pressure, noncompliant balloon was at the operator's discretion and primarily based on anticipation of suboptimal results with a conventional balloon due to calcification and length of lesion.

Patient with lesions less than 100 mm in length were excluded. Lesions were considered separate if the plaques were more than 5 cm apart. In total, 20 patients with 21 critically ischemic limbs were retrospectively analyzed.

Endovascular procedure and wound treatment

Before the procedure, patients were evaluated with a highresolution duplex ultrasound (SonoSite Edge II, FUJIF-ILM SonoSite, Bothell, WA, USA) by a trained ultrasound technician. Computer Tomography angiography (CTA)

was performed if aortoiliac lesions were suspected or if duplex findings were discordant with clinical findings. All patients were pretreated with aspirin (100 mg) and underwent preparation for angioplasty according to the institutional protocol. Prior to the procedure an anesthesiologist administered monitored intravenous sedation and a popliteal nerve block¹⁴ under ultrasound guidance (SonoSite Edge II). This was done primarily to allow surgical debridement of the wounds which was routinely done in the same setting after endovascular intervention. The nerve block had a secondary benefit of allowing high-pressure angioplasty without excessive pain.

Antegrade access to the femoral artery was created using a 18G needle using the Seldinger technique under ultrasound guidance (SonoSite Edge II).¹⁵ A 5 or 6F antegrade 45 cm sheath (BRITE TIP, Cordis, Santa Clara, CA, USA) was placed in case of isolated BTK lesions. In case of inflow lesions, a shorter antegrade sheath (BRITE TIP) or a crossover sheath (Flexor, Cook Medical, Bloomington, IN, USA) was placed. Inflow lesions were treated by balloon angioplasty using POBA. Systematic anticoagulation was performed with intra-arterial administration of 3000 units unfractionated heparin, followed by 1000 units per subsequent hour of intervention according to institutional protocol.

PTA was performed as follows. Lesions were crossed with a 0.014-inch moderate-support 300 cm long guidewire (PT² moderate support, Boston Scientific, Marlborough, USA). A 2-mm balloon (Amphirion Deep, Medtronic, Dublin, Ireland) was inserted to cross and predilate the lesion if necessary. Final balloon angioplasty was performed with the JADE balloon. The balloon was inflated (EncoreTM, Boston Scientific, Marlborough, MA, USA) for 90 seconds with a pressure of 22 to 24 atm. The diameter of the balloon was based on the visual diameter of the vessel diameter on a 1:1 basis. The length of the balloon was chosen according to the length of the lesion. No adjunctive scoring balloons, atherectomy, DCBs or stents were used. The result was assessed on completion angiography. In case of non-flow limiting residual stenosis of 30%, this was accepted without placement of a stent. After the procedure, patients were prescribed aspirin at 100 mg/day orally.

Wound debridement, drainage of an infected phlegmon or minor amputation was performed simultaneously in all patients when necessary.

Follow-up

Patients were monitored in a multidisciplinary team lead by the attending vascular surgeon. Simultaneous wound care and clinical assessment of perfusion was performed weekly at least for 1 month, followed by at least fortnightly until the wound healed. Wound care was done in the hospital by a dedicated nurse or podiatric nurse. Reintervention was only performed if wound healing was deemed to be poor as seen by poor granulation or failure in wound size reduction and if clinical assessment revealed a weak or absent pulse. Reintervention was performed by balloon angioplasty with or without stenting.

Data collection, end points, and definitions

Patient demographics, baseline risk factors, and laboratory, angiographic, and procedural data were retrospectively collected. Data were derived from electronic medical records, clinical records, imaging reports, and laboratory reports. Angiographic data were derived by analyzing the procedural angiographic images, which were independently assessed by 2 experienced interventionalists (G.A. and R.F.) who were not involved in the intervention.

The primary end point was technical success. Secondary outcomes were procedure-related complications, limb salvage rate, amputation-free survival (AFS), wound healing, overall survival, resolution of CLTI without TLR, and freedom from clinically driven target lesion reintervention (CD-TLR) at 2 years.

Technical success was defined as ability to cross the lesion and fully efface the balloon, leaving no residual stenosis (<30%) seen on angiography. Lesions were considered separate if more than 5 cm apart. Limb salvage was defined as avoidance of major amputation (above the ankle). AFS was defined as avoidance of major amputation or death. Freedom of CD-TLR was defined as avoidance of any clinically driven repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. Resolution of CLTI without CD-TLR was defined as absence of rest pain and complete wound healing without the need for CD-TLR. Wounds were considered healed if the wound was fully epithelized, with or without a skin graft. In patients who underwent major amputation, the time to wound healing was considered to be infinite.

Statistical analysis

Quantile-quantile (Q-Q) plots were analyzed to determine whether continuous variables followed a normal distribution. If the points in the Q-Q plot lie on a straight diagonal line, the data is defined as normally distributed. Normally distributed continuous variables are expressed as mean and standard deviation and were compared using the

TABLE I.—Baseline characteristics.	
Variables	Value
N. patients	20
N. limbs	21
Sex, male	14 (70.0%)
Age, years	65.90±10.9
Left limb	12 (57.1%)
Comorbidities	
Hypertension	18 (90.0%)
Diabetes	19 (95.0%)
Hyperlipidemia	16 (80.0%)
Hemodialysis	4 (20.0%)
Cerebrovascular accident	4 (20.0%)
Chronic kidney disease	10 (50.0%)
Laboratory results	
Serum creatinine. µmol/L	117 (85-211)
GFR <30 mL/min/1.73 m ²	6 (30.0%)
Rutherford	
5	18 (85.7%)
6	3 (14.3%)
Mobility	
ADL assisted	3 (15.0%)
Community ambulation	16 (80.0%)
Continuous data are presented as m range). Categorical data are present GFR: glomerular filtration rate; ADL:	ed as number (percentage).

paired-samples *t*-test. Statistical significance was defined as P<0.05. Nonnormally distributed data are presented as median and the interquartile range. Categorical variables are expressed as number with percentage (%). Limb salvage rate, AFS rate, wound healing rate, overall survival rate, freedom from TLR, and resolution of CLTI without TLR were calculated by Kaplan-Meier analysis. Statistical analysis was performed using SPSS 23 software (IBM, Armonk, NY, USA).

Results

Patient characteristics

The high-pressure, noncompliant balloon was used to treat 23 lesions in 21 limbs of 20 patients (70% male). Patients were a mean age of 65 ± 11 years. Comorbidities included diabetes in 95%, chronic kidney disease in 50%, and dialysis in 20%. All patients had Rutherford 5 and 6 CLTI. Patient demographics and baseline characteristics are reported in Table I.

Lesion details

All lesions were de novo and were recanalized intraluminally. The mean lesion length was 374 ± 140 mm, with 21 (91.3%) classified as TASC C or D lesions. Of all treated

Variables	Total	
Vessels treated	40	
Anterior tibial artery	19 (47.5%)	
Dorsalis pedis	11 (27.5%)	
Plantar arch	5 (12.5%)	
Posterior tibial artery	3 (7.5%)	
Peroneal artery	1 (2.5%)	
Plantar lateral artery	1 (2.5%)	
Lesions	23	
Occlusions	13 (56.5%)	
Lesion length, mm	374.8±140.03	
Vessel diameter treated, mm	3.0±0.15	
PARC classification		
Focal	1 (4.8%)	
Moderate	4 (19.0%)	
Severe	18 (78.3%)	
TASC classification		
A	1 (4.8%)	
В	1 (4.8%)	
С	10 (43.5%)	
D	11 (47.8%)	

Continuous data are presented as mean±SD. Categorical data are presented as number (percentage). PARC: Peripheral Academic Research Consortium; TASC: Trans-Atlantic Inter-

PARC: Peripheral Academic Research Consortium; TASC: Trans-Atlantic Inter-Society Consensus Document.

TABLE III.—Pre- and post-procedural values of runoff vessels.				
Variable	Pre	Post	P value	
Runoff vessels	0.62±0.67	1.57±0.60	< 0.001	
Runoff vessels to the foot	0.19±0.40	1.14±0.36	< 0.001	

Data are presented as mean±SD.

lesions, 11 (47.8%) were confined in the above-the-ankle arteries and 12 (52.2%) lesions extended to below-the-ankle arteries. Of these lesions, 6 (26.1%) extended from the anterior tibial artery to the dorsalis pedis, 5 (21.8%) from the anterior tibial artery to the plantar arch and 1 (4.3%) from the posterior tibial artery to the plantar lateral artery. These 23 lesions treated spanned 40 arteries as the lesion was contiguous across more than one vessel.

Thirteen (56.5%) of the treated lesions were occlusions. Calcification was noted to be severe according to the Peripheral Academic Research Consortium (PARC) classification¹⁶ for 18 lesions (78.3%). In six limbs (28.6%), concomitant inflow lesions were treated in the same procedure.

Procedure

The mean balloon diameter used was 3.0 ± 0.07 mm, and the mean balloon length used was 106 ± 22.9 mm. Angio-

HUIZING

HIGH-PRESSURE, NON COMPLIANT BALLOON ANGIOPLASTY

graphic details are summarized in Table II, and the mean preprocedural and postprocedural runoff vessels are reported in Table III.

Thirty-day outcome

Technical success was achieved in 22 lesions (95.7%). One patient had residual recoil of 30% that was deemed non-flow limiting. No stents were inserted. No perforation, dis-

section, distal embolization, groin hematoma, or stroke occurred periprocedurally. One patient died of cardiac arrest (pulseless electrical activity) 2 days after the procedure. No other complications occurred within 30 days post procedure.

Subsequent follow-up

Beyond 30-days, a total of 6 other deaths occurred due to myocardial infarction (N.=1), ulcerative colitis (N.=1), ischemic




Figure 1.—Limb salvage.




Figure 3.—Wound healing.

Survival function 100 80 Amputation-free survival 60 40 20 18 12 24 30 36 Time after procedure (months) Months 0 12 18 24 30 36 N. at risk 18 85.7 18 85.7 14 71.4 13 66.3 21 100 17 81.0 8 56.1

Figure 2.—Amputation-free survival.




Figure 4.—Overall survival.




Figure 5.—Freedom from CD-TLR.

bowel (N.=1) and an unknown cause (N.=3). During followup, a total of 4 major amputations deemed necessary because of severe infection (N.=3) and unsolvable gangrene (N.=1).

Reintervention deemed necessary in 6 limbs. In all limbs, lesions were treated by angioplasty using the JADE balloon (N.=5) or a drug coated balloon (N.=1). In 1 patient, additional stent placement (XIENCE prime, Abbott, Abbott Park, IL, USA) was required. No patient underwent a surgical bypass.

At 2 and 3 years, limb salvage was 84.7% and 78.7% and AFS was 71.4% and 56.1%, respectively. Wound healing rate was 81.0% and 85.7%, with a median time to wound healing of 104 days (range, 48–907 days). Overall survival was 75.0% and 64.3%, freedom from CD-TLR was 77.6% and 63.5% at 2 and 3 years, respectively. Resolution of CLTI without TLR was 81.0% at 2 and 3 years. Kaplan-Meier analyses are shown in Figure 1, 2, 3, 4, 5, and 6. The median time to follow-up was 31 months (range, 0-45 months).

Discussion

This study shows that angioplasty with a high-pressure, noncompliant balloon is safe and feasible for the treatment of severely calcified infrapopliteal lesions. Although endovascular treatment options are expanding and technical success rates of treatment with POBA are increasing, it still often fails. Failure occurs mainly in the more complex lesions, in TASC C and D lesions.¹⁻³ In this study a tech-




Figure 6.—Resolution of CLTI without CD-TLR

nical success rate of 95.2% was achieved in a population with 91% TASC C and D lesions and therefore it suggests that high-pressure, noncompliant balloon angioplasty can be used as an endovascular treatment option for complex lesions.

Even though the combination of high-pressure and noncompliance could be effective in treating complex lesions, it may also lead to an increased risk of vessel damage, including dissections and artery rupture. These complications were not seen in any of the patients in the present study, but artery rupture has been described in coronary studies.¹² The ruptures occurred when an inflation pressures of 30-40 atm were applied. Furthermore, the balloon size was based on angiographic estimation without using intravascular imaging. When applying pressures of 30-40 atm, special attention should be paid to the size of the balloon to reduce the risk of artery rupture. By inflating the high-pressure, noncompliant balloon to 22-24 atm for 90 seconds in the present study, no immediate procedurally related angiographic complications occurred.

One patient died of cardiac arrest within 30 days after the procedure. This patient was 85 years old, had a left ventricular ejection fraction of 30%, was known to have segmental wall-motion abnormalities of the left ventricle and was diagnosed with chronic kidney disease. The death occurred despite prior optimization with medical therapy and periprocedural monitoring by an anesthetic team. There was no record of severe pain experienced that may have exacerbated a coronary condition. This event high-

HUIZING

lights the fragile status of CLTI patients. The Poor-Risk Patients With and Without Revascularization Therapy for Critical Limb Ischemia (PRIORITY) registry¹⁷ also observed that patients with heart failure who underwent revascularization were at a higher risk of death. In addition, the study by Martinez *et al.*¹⁸ reported increasing age and below-the-knee intervention as risk factors for major amputation or death. In selecting patients for endovascular procedures, attention should be paid to the patients' co-morbidities and the periprocedural risks.

There are several other treatment modalities designed for complex lesions, such as cutting balloons and atherectomy devices. Cutting balloons have shown to be technically successful in 96-100% of the cases,^{19, 20} but with a complication rate of 8.9%²⁰ including dissections and vessel leakage. Studies that investigated atherectomy devices report also high technical success rates (99%), but with complication rates ranging from 3.4% to 27.5%.²¹⁻²³ Complications included perforation, distal embolization and dissections among others. Therefore, treatment with these devices should be performed with caution in infrapopliteal arteries.

Compared to POBA, the freedom from CD-TLR rate found in the present study is higher (89.2%) at 1-year follow-up. A recent meta-analysis⁵ reported a freedom from TLR rate of 71.6% after POBA in infrapopliteal arteries. The explanation for the higher freedom from CD-TLR rate found in this study compared with the recent meta-analysis remains unclear. A possible explanation could lie with the good angiographic results seen on completion angiogram after a combination of high-pressure, noncompliant balloon and prolonged inflation time of 90 seconds. In the study by Baumann et al.6 occurrence of early elastic recoil, defined as lumen compromise >10%, was assessed by comparing minimal lumen diameter at baseline, immediately after PTA and 15 minutes after PTA. Interestingly, elastic recoil was found in 97% of the patients with a mean luminal compromise of 29% 15 minutes post PTA. However, the assessment of elastic recoil 15 minutes after angioplasty was not assessed in this study. Therefore, the true effect of a high-pressure, noncompliant balloon and the effect of prolonged inflation time on elastic recoil are undefined and could be further explored in the future.

The pathophysiology of restenosis is poorly understood, but early elastic recoil, arterial injury and residual dissection could be contributory factors to the high restenosis rates.^{6, 24-26} The high-pressure, noncompliant balloon may possibly deal with elastic recoil and reducing the risk of arterial injury because of the combination of the high pressure and the noncompliance. Disrupting the fibro-calcific plaque reduces the risk of recoil²⁷ which is sometimes difficult to achieve with POBA. A high pressure may be required in these calcified lesions to disrupt the plaque. In addition, the risk of vessel damage may be reduced by the non-compliance of the balloon that allows the balloon to explant uniformly and thereby prevents over-expansion of the balloon in the more compliant segment.^{12, 13} However, this study did not include assessment arterial plaque disruption or vessel damage thus no hard conclusions can be drawn. More research is necessary to support these hypotheses.

Limitations of the study

This retrospective study has limitations due to its design. There was no comparative group and it includes a small sample size. A completion angiogram was performed, but no further angiograms or duplex ultrasounds were performed to assess recoil and target vessel patency. Hence no meaningful conclusions could be drawn on the effect of high pressure and noncompliant angioplasty on vessel patency. However, data on clinically driven reinterventions served as a surrogate indication of clinically patency. No routine hemodynamic measurement was performed as per institution practice in view of the calcified nature of the vessels in a predominantly diabetic population. However, this study is the first to analyze the safety and feasibility of the high-pressure, noncompliant balloon in long, severely calcified infrapopliteal lesions.

Conclusions

This study shows that a high-pressure, noncompliant balloon is feasible for the treatment of infrapopliteal and inframalleolar calcified lesions. The outcome of this study can be used as a stepping stone for further research to fully investigate the safety and effectiveness of high-pressure, noncompliant balloons in comparison with POBA.

References

1. Lo RC, Darling J, Bensley RP, Giles KA, Dahlberg SE, Hamdan AD, *et al.* Outcomes following infrapopliteal angioplasty for critical limb ischemia. J Vasc Surg 2013;57:1455–63, discussion 1463–4.

2. Tewksbury R, Pearch B, Redmond K, Harper J, Klein K, Quinn J. Outcomes of infrapopliteal endoluminal intervention for transatlantic intersociety consensus C and D lesions in patients with critical limb ischaemia. ANZ J Surg 2014;84:866–70.

3. Giles KA, Pomposelli FB, Spence TL, Hamdan AD, Blattman SB, Panossian H, *et al.* Infrapopliteal angioplasty for critical limb ischemia: relation of TransAtlantic InterSociety Consensus class to outcome in 176 limbs. J Vasc Surg 2008;48:128–36.

HIGH-PRESSURE, NON COMPLIANT BALLOON ANGIOPLASTY

4. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007;45(Suppl S):S5–67.

5. Ipema J, Huizing E, Schreve MA, de Vries JP, Ünlü Ç. Editor's Choice -Drug Coated Balloon Angioplasty vs. Standard Percutaneous Transluminal Angioplasty in Below the Knee Peripheral Arterial Disease: A Systematic Review and Meta-Analysis. Eur J Vasc Endovasc Surg 2020;59:265–75.

6. Baumann F, Fust J, Engelberger RP, Hügel U, Do DD, Willenberg T, *et al.* Early recoil after balloon angioplasty of tibial artery obstructions in patients with critical limb ischemia. J Endovasc Ther 2014;21:44–51.

7. Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, *et al.*; GVG Writing Group. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg 2019;69(6S):3S–125S, e40.

8. Ambler GK, Radwan R, Hayes PD, Twine CP. Atherectomy for peripheral arterial disease. Cochrane Database Syst Rev 2014;(3):CD006680.

9. Varcoe RL, Paravastu SC, Thomas SD, Bennett MH. The use of drugeluting stents in infrapopliteal arteries: an updated systematic review and meta-analysis of randomized trials. Int Angiol 2019;38:121–35.

10. Liu X, Zheng G, Wen S. Drug-eluting stents versus control therapy in the infrapopliteal disease: A meta-analysis of eight randomized controlled trials and two cohort studies. Int J Surg 2017;44:166–75.

11. Almasri J, Adusumalli J, Asi N, Lakis S, Alsawas M, Prokop LJ, *et al.* A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia. J Vasc Surg 2018;68:624–33.

12. Secco GG, Buettner A, Parisi R, Pistis G, Vercellino M, Audo A, *et al.* Clinical experience with very high-pressure dilatation for resistant coronary lesions. Cardiovasc Revasc Med 2019;20:1083–7.

13. Secco GG, Ghione M, Mattesini A, Dall'Ara G, Ghilencea L, Kilickesmez K, *et al.* Very high-pressure dilatation for undilatable coronary lesions: indications and results with a new dedicated balloon. Euro-Intervention 2016;12:359–65.

14. Creech C, Meyr AJ. Techniques of popliteal nerve regional anesthesia. J Foot Ankle Surg 2013;52:681–5.

15. Seldinger SI. Catheter replacement of the needle in percutaneous arteriography; a new technique. Acta Radiol 1953;39:368–76.

16. Patel MR, Conte MS, Cutlip DE, Dib N, Geraghty P, Gray W, *et al.* Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). J Am Coll Cardiol 2015;65:931–41.

17. Iida O, Takahara M, Soga Y, Azuma N, Nanto S, Uematsu M; PRIOR-ITY Investigators. Prognostic Impact of Revascularization in Poor-Risk Patients With Critical Limb Ischemia: The PRIORITY Registry (Poor-Risk Patients With and Without Revascularization Therapy for Critical Limb Ischemia). JACC Cardiovasc Interv 2017;10:1147–57.

18. Martínez M, Sosa C, Velescu A, Llort C, Elosua R, Clarà A. Predictive factors of a poor outcome following revascularization for critical limb ischemia: implications for practice. Int Angiol 2018;37:370–6.

19. Ansel GM, Sample NS, Botti III CF Jr, Tracy AJ, Silver MJ, Marshall BJ, *et al.* Cutting balloon angioplasty of the popliteal and infrapopliteal vessels for symptomatic limb ischemia. Catheter Cardiovasc Interv 2004;61:1–4.

20. Canaud L, Alric P, Berthet JP, Marty-Ané C, Mercier G, Branchereau P. Infrainguinal cutting balloon angioplasty in de novo arterial lesions. J Vasc Surg 2008;48:1182–8.

21. Das T, Mustapha J, Indes J, Vorhies R, Beasley R, Doshi N, *et al.* Technique optimization of orbital atherectomy in calcified peripheral lesions of the lower extremities: the CONFIRM series, a prospective multicenter registry. Catheter Cardiovasc Interv 2014;83:115–22.

22. Khalili H, Jeon-Slaughter H, Armstrong EJ, Baskar A, Tejani I, Shammas NW, *et al.* Atherectomy in below-the-knee endovascular interventions: one-year outcomes from the XLPAD registry. Catheter Cardiovasc Interv 2019;93:488–93.

23. Janas AJ, Milewski KP, Buszman PP, Trendel W, Kolarczyk-Haczyk A, Hochuł M, *et al.* Long term outcomes in diabetic patients treated with atherectomy for peripheral artery disease. Cardiol J 2018. [Epub ahead of print]

24. Baumann F, Groechenig E, Diehm N. Does patency matter in patients with critical limb ischemia undergoing endovascular revascularization? Ann Vasc Dis 2014;7:11–6.

25. Brodmann M, Wissgott C, Holden A, Staffa R, Zeller T, Vasudevan T, *et al.* Treatment of infrapopliteal post-PTA dissection with tack implants: 12-month results from the TOBA-BTK study. Catheter Cardiovasc Interv 2018;92:96–105.

26. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, *et al.* Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992;19:267–74.

27. Jain SP, Jain A, Collins TJ, Ramee SR, White CJ. Predictors of restenosis: a morphometric and quantitative evaluation by intravascular ultrasound. Am Heart J 1994;128:664–73.

Conflicts of interest.—The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

History.—Article first published online: May 13, 2020. - Manuscript accepted: May 11, 2020. - Manuscript revised: April 21, 2020. - Manuscript received: February 19, 2020.